Amgen bets on $1.9-billion Five Prime deal to grow in Asia-Pacific oncology market
(Reuters) - Drugmaker Amgen Inc is buying Five Prime Therapeutics for about $1.9 billion to expand its line of gastric cancer drug candidates and its presence in Asia-Pacific, the companies said on Thursday.
